ESCO1

Summary

ESCO1 (establishment of sister chromatid cohesion N-acetyltransferase 1, HGNC:24645) is a protein-coding gene on chromosome 18q11.2, encoding N-acetyltransferase ESCO1 (Q5FWF5). Acetyltransferase required for the establishment of sister chromatid cohesion.

Enables identical protein binding activity; protein-lysine-acetyltransferase activity; and zinc ion binding activity. Involved in peptidyl-lysine acetylation; post-translational protein acetylation; and regulation of DNA replication. Located in chromatin.

Source: NCBI Gene 114799 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 126 total — 1 pathogenic
• MANE Select transcript: NM_052911

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24645
Approved symbol	ESCO1
Name	establishment of sister chromatid cohesion N-acetyltransferase 1
Location	18q11.2
Locus type	gene with protein product
Status	Approved
Aliases	ESO1, EFO1, KIAA1911
Ensembl gene	ENSG00000141446
Ensembl biotype	protein_coding
OMIM	609674
Entrez	114799

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 13 protein_coding, 1 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000269214, ENST00000383276, ENST00000580101, ENST00000622333, ENST00000892204, ENST00000892205, ENST00000923541, ENST00000923542, ENST00000923543, ENST00000923544, ENST00000923545, ENST00000923546, ENST00000923547, ENST00000923548, ENST00000963036

RefSeq mRNA: 1 — MANE Select: NM_052911 NM_052911

CCDS: CCDS32800

Canonical transcript exons

ENST00000269214 — 12 exons

Exon	Start	End
ENSE00000948585	21567980	21568094
ENSE00000948586	21564203	21564317
ENSE00000948587	21560859	21560990
ENSE00001037663	21566146	21566206
ENSE00001324551	21573314	21575430
ENSE00001349284	21575672	21575777
ENSE00001349700	21584310	21584440
ENSE00001663862	21529284	21530490
ENSE00002702615	21600623	21600704
ENSE00003567216	21539920	21540009
ENSE00003598306	21536042	21536185
ENSE00003671195	21532473	21532660

Expression profiles

Bgee: expression breadth ubiquitous, 259 present calls, max score 95.85.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 16.9073 / max 380.5549, expressed in 1758 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
171309	13.9862	1704
171310	1.9661	1103
171313	0.3038	109
171312	0.2679	119
171311	0.2325	78
171314	0.1509	61

Top tissues by expression

259 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
oviduct epithelium	UBERON:0004804	95.85	gold quality
buccal mucosa cell	CL:0002336	95.66	gold quality
tendon of biceps brachii	UBERON:0008188	94.96	gold quality
epithelial cell of pancreas	CL:0000083	93.26	gold quality
tibialis anterior	UBERON:0001385	92.40	gold quality
secondary oocyte	CL:0000655	90.74	gold quality
tendon	UBERON:0000043	90.70	gold quality
calcaneal tendon	UBERON:0003701	90.31	gold quality
deltoid	UBERON:0001476	90.27	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	89.53	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	89.32	gold quality
epithelium of nasopharynx	UBERON:0001951	89.22	gold quality
palpebral conjunctiva	UBERON:0001812	88.59	gold quality
adrenal tissue	UBERON:0018303	87.87	gold quality
kidney epithelium	UBERON:0004819	87.80	gold quality
amniotic fluid	UBERON:0000173	87.71	gold quality
eye	UBERON:0000970	87.68	gold quality
medial globus pallidus	UBERON:0002477	87.61	gold quality
thymus	UBERON:0002370	87.60	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	87.47	gold quality
ileal mucosa	UBERON:0000331	87.41	gold quality
testis	UBERON:0000473	87.23	gold quality
cartilage tissue	UBERON:0002418	87.19	gold quality
oocyte	CL:0000023	86.90	gold quality
gingival epithelium	UBERON:0001949	86.33	gold quality
right testis	UBERON:0004534	86.31	gold quality
left ventricle myocardium	UBERON:0006566	86.27	silver quality
left testis	UBERON:0004533	86.25	gold quality
endothelial cell	CL:0000115	86.18	gold quality
bone marrow	UBERON:0002371	86.03	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.97

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

69 targeting ESCO1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-33A-5P	99.99	68.62	1055
HSA-MIR-33B-5P	99.99	68.58	1062
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4650-5P	99.98	64.69	999
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-3686	99.90	70.53	2432
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-12119	99.87	68.35	1653
HSA-MIR-4698	99.84	71.41	4303
HSA-MIR-548AZ-5P	99.83	69.94	3230
HSA-MIR-548T-5P	99.83	69.91	3220
HSA-MIR-6515-3P	99.82	68.19	1933
HSA-MIR-4495	99.82	72.08	3080
HSA-MIR-6875-3P	99.82	70.26	2983
HSA-MIR-577	99.78	69.13	2479
HSA-MIR-1200	99.71	70.42	1838
HSA-MIR-587	99.64	70.86	2611
HSA-MIR-4666B	99.64	68.69	1282

Literature-anchored findings (GeneRIF, showing 14)

• identification of the first full-length human ortholog of yeast Ctf7p and characterization of its enzymatic activity, localization and novel genetic composition (PMID:14576321)
• EFO1 and EFO2 are targeted to different chromosome structures to help establish or maintain sister-chromatid cohesion (PMID:15958495)
• This study identified a molecular target for the acetyltransferase Eco1 and revealed that Smc3 acetylation is a conserved mechanism in regulating sister chromatid cohesion. (PMID:18614053)
• Variants in ESCO1 is associated with predisposition for TMPRSS2-ERG fusion in prostate cancer. (PMID:19861517)
• this is the first evidence that Eco1 represses transcription by interacting with histone demethylase, LSD1 to convert chromatin to inactive state. (PMID:20331966)
• This is the first report of somatic mutations within ESCO1 and CHTF18 in endometrial tumors and of MRE11A mutations in microsatellite-stable endometrial tumors. (PMID:23755103)
• By interacting with a unique domain of Esco1, Pds5 recruits Esco1 to chromatin-bound cohesin complexes to form cohesion. (PMID:26051894)
• Data show that acetyltransferase Esco1 colocalizes with cohesin throughout the cell cycle and down-regulates expression of neighboring genes. (PMID:26305936)
• our findings indicated that ESCO1 may play an important role in human bladder cancer, and ESCO1 might serve as a novel target and prognosis factor for human bladder cancer. (PMID:26547586)
• these studies reveal the molecular basis for SMC3 acetylation by ESCO1 and have broader implications for understanding the structure/function of non-histone acetyltransferases. (PMID:27803161)
• Data indicate that Esco1 and Esco2 contribute to distinct and separable activities of cohesin in vertebrate cells. (PMID:28847955)
• DDX11, ESCO1 and ESCO2 control different fractions of cohesin that are spatially and mechanistically separated. (PMID:31935221)
• ESCO1 and CTCF enable formation of long chromatin loops by protecting cohesin(STAG1) from WAPL. (PMID:32065581)
• Alternative catalytic residues in the active site of Esco acetyltransferases. (PMID:32555289)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	esco1	ENSDARG00000077057
mus_musculus	Esco1	ENSMUSG00000024293
rattus_norvegicus	Esco1	ENSRNOG00000014031

Paralogs (5): POLI (ENSG00000101751), POLK (ENSG00000122008), REV1 (ENSG00000135945), POLH (ENSG00000170734), ESCO2 (ENSG00000171320)

Protein

Protein identifiers

N-acetyltransferase ESCO1 — Q5FWF5 (reviewed: Q5FWF5)

Alternative names: CTF7 homolog 1, Establishment factor-like protein 1, Establishment of cohesion 1 homolog 1

All UniProt accessions (2): A0A0C4DH04, Q5FWF5

UniProt curated annotations — full annotation on UniProt →

Function. Acetyltransferase required for the establishment of sister chromatid cohesion. Couples the processes of cohesion and DNA replication to ensure that only sister chromatids become paired together. In contrast to the structural cohesins, the deposition and establishment factors are required only during S phase. Acts by mediating the acetylation of cohesin component SMC3.

Subunit / interactions. The subunit structure is controversial. Monomer. Homodimer.

Subcellular location. Nucleus. Chromosome.

Tissue specificity. Widely expressed. Expressed in heart, brain, liver, placenta, lung, kidney and pancreas. Highly expressed in muscle.

Post-translational modifications. Phosphorylated during mitosis, when associated with chromosomes.

Domain organisation. The N-terminal region seems to be responsible for association with chromosomes, thus excluding any involvement of the Zn finger in this process.

Miscellaneous. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay.

Similarity. Belongs to the acetyltransferase family. ECO subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
Q5FWF5-1	1	yes
Q5FWF5-2	2

RefSeq proteins (1): NP_443143* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR028005	AcTrfase_ESCO_Znf_dom	Domain
IPR028009	ESCO_Acetyltransf_dom	Domain

Pfam: PF13878, PF13880

Catalyzed reactions (Rhea), 1 shown:

• L-lysyl-[protein] + acetyl-CoA = N(6)-acetyl-L-lysyl-[protein] + CoA + H(+) (RHEA:45948)

UniProt features (70 total): mutagenesis site 22, compositionally biased region 11, strand 10, helix 6, region of interest 5, binding site 3, sequence conflict 3, modified residue 2, splice variant 2, sequence variant 2, chain 1, zinc finger region 1, cross-link 1, turn 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
4MXE	X-RAY DIFFRACTION	2.6
5T53	X-RAY DIFFRACTION	2.7

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5FWF5-F1	52.74	0.21

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (3): 772–774; 780–785; 812–814

Post-translational modifications (3): 200, 412, 332

Mutagenesis-validated functional residues (22):

Position	Phenotype
622	no effect on association with chromosomes.
640	strongly decreased enzyme activity.
643	strongly decreased enzyme activity.
644	strongly decreased enzyme activity.
690	strongly decreased enzyme activity.
725	strongly decreased enzyme activity.
732	strongly decreased enzyme activity.
735	strongly decreased enzyme activity.
736	strongly decreased enzyme activity.
756	strongly decreased enzyme activity.
768	loss of autoacetylation.
770	strongly decreased enzyme activity.
771	strongly decreased enzyme activity.
773	decreased thermal stability. strongly decreased enzyme activity.
779–780	significant reduction in autoacetylation.
780	nearly abolishes autoacetylation.
782–783	significant reduction in autoacetylation.
786	decreased thermal stability. strongly decreased enzyme activity.
789	reduced autoacetylation.
803	strongly reduced autoacetylation.
809	strongly decreased enzyme activity.
815	strongly decreased enzyme activity. no effect on thermal stability.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-2468052	Establishment of Sister Chromatid Cohesion

MSigDB gene sets: 132 (showing top): GOBP_CHROMOSOME_ORGANIZATION, MYOGENIN_Q6, GCAAGGA_MIR502, ATGCAGT_MIR217, CAGCTG_AP4_Q5, GGCNKCCATNK_UNKNOWN, GOBP_PEPTIDYL_LYSINE_MODIFICATION, GOBP_PROTEIN_ACETYLATION, MILI_PSEUDOPODIA_HAPTOTAXIS_UP, GOBP_SISTER_CHROMATID_COHESION, CAATGCA_MIR33, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, TGTTTAC_MIR30A5P_MIR30C_MIR30D_MIR30B_MIR30E5P, CUI_TCF21_TARGETS_2_DN, GOBP_PROTEIN_ACYLATION

GO Biological Process (5): regulation of DNA replication (GO:0006275), sister chromatid cohesion (GO:0007062), mitotic sister chromatid cohesion (GO:0007064), peptidyl-lysine acetylation (GO:0018394), post-translational protein acetylation (GO:0034421)

GO Molecular Function (8): N-acetyltransferase activity (GO:0008080), zinc ion binding (GO:0008270), acetyltransferase activity (GO:0016407), identical protein binding (GO:0042802), protein-lysine-acetyltransferase activity (GO:0061733), transferase activity (GO:0016740), acyltransferase activity (GO:0016746), metal ion binding (GO:0046872)

GO Cellular Component (4): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), chromosome (GO:0005694)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
S Phase	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein acetylation	2
cellular anatomical structure	2
DNA replication	1
regulation of DNA metabolic process	1
cell cycle process	1
chromosome organization	1
sister chromatid cohesion	1
peptidyl-lysine modification	1
post-translational protein modification	1
acetyltransferase activity	1
transition metal ion binding	1
acyltransferase activity, transferring groups other than amino-acyl groups	1
protein binding	1
protein N-acetyltransferase activity	1
catalytic activity	1
transferase activity	1
cation binding	1
chromosome	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

2376 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ESCO1	PDS5A	Q29RF7	981
ESCO1	SMC3	Q9UQE7	976
ESCO1	WAPL	Q7Z5K2	967
ESCO1	CHTF18	Q8WVB6	947
ESCO1	STAG1	Q8WVM7	895
ESCO1	RAD21	O60216	886
ESCO1	CHTF8	P0CG13	878
ESCO1	GLYATL1	Q969I3	872
ESCO1	MAU2	Q9Y6X3	868
ESCO1	DSCC1	Q9BVC3	858
ESCO1	NAT10	Q9H0A0	850
ESCO1	ESPL1	Q14674	850
ESCO1	RFC2	P32846	804
ESCO1	HGSNAT	Q68CP4	803
ESCO1	NAA10	P41227	794
ESCO1	NIPBL	Q6KC79	794

IntAct

7 interactions, top by confidence:

A	B	Type	Score
ESCO1	PDIA3	psi-mi:“MI:0915”(physical association)	0.400
Esco1	ESCO1	psi-mi:“MI:0915”(physical association)	0.400
CALM1	MYO1C	psi-mi:“MI:0914”(association)	0.350
CALM2	MYO1C	psi-mi:“MI:0914”(association)	0.350
CALM3	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
H2BC21	SMCHD1	psi-mi:“MI:0914”(association)	0.350

BioGRID (44): ESCO1 (Affinity Capture-MS), ESCO1 (Affinity Capture-MS), ESCO1 (Affinity Capture-MS), ESCO1 (Affinity Capture-MS), ESCO1 (Affinity Capture-MS), ESCO1 (Affinity Capture-MS), ESCO1 (Affinity Capture-MS), ESCO1 (Affinity Capture-MS), ESCO1 (Affinity Capture-MS), ESCO1 (Affinity Capture-MS), ESCO1 (Affinity Capture-MS), ESCO1 (Affinity Capture-MS), ESCO1 (Affinity Capture-MS), ESCO1 (Affinity Capture-RNA), ESCO1 (Affinity Capture-RNA)

ESM2 similar proteins: A0A1L8GR68, A2CG63, A2VE56, D3ZHS6, E6ZGB4, F7AQ22, O75376, O88974, P0C6S7, P57768, P57769, Q15047, Q2YDJ8, Q2YDW7, Q4KKX4, Q4LE39, Q52L14, Q5F3F2, Q5F3N6, Q5FWF5, Q5R6Q7, Q5VVJ2, Q60974, Q66JB6, Q68FE8, Q69Z61, Q69Z66, Q69Z69, Q6N043, Q6NXK2, Q7Z6G8, Q86YI8, Q8BIZ1, Q8C080, Q8K2W6, Q8QFX1, Q92560, Q96N64, Q98925, Q99PU7

Diamond homologs: A1JNY3, A1RMZ5, A1S8M3, A3D147, A3N148, A4TPK8, A5F5Y1, A6WRW5, A7FLI9, A7MEN4, A9L0T3, B0BPX9, B8F542, C3LQ59, O42917, Q086K1, Q12Q05, Q1C4D9, Q1CLD4, Q487H6, Q56NI9, Q5FWF5, Q5SPR8, Q65TG8, Q66DZ7, Q69Z69, Q6C668, Q6D1H8, Q7MID6, Q87MB4, Q8CIB9, Q8DBI7, Q8ZBZ9, Q9JJN0, Q9KPS5, Q9Y253, A7UL74, Q9VS50

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
CDC7	down-regulates	ESCO1	phosphorylation
CDK1	down-regulates	ESCO1	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

126 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	108
Likely benign	2
Benign	1

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
2445432	GRCh37/hg19 18q11.1-11.2(chr18:18856932-19159898)x1	Pathogenic

SpliceAI

2482 predictions. Top by Δscore:

Variant	Effect	Δscore
18:21532472:C:G	donor_loss	1.0000
18:21532656:TAGCC:T	acceptor_gain	1.0000
18:21532657:AGCC:A	acceptor_gain	1.0000
18:21532658:GCC:G	acceptor_gain	1.0000
18:21532659:CC:C	acceptor_gain	1.0000
18:21532659:CCC:C	acceptor_gain	1.0000
18:21532660:CC:C	acceptor_gain	1.0000
18:21532660:CCTAC:C	acceptor_loss	1.0000
18:21532661:C:CC	acceptor_gain	1.0000
18:21532661:C:CG	acceptor_loss	1.0000
18:21532671:C:CT	acceptor_gain	1.0000
18:21532672:A:T	acceptor_gain	1.0000
18:21532676:A:AC	acceptor_gain	1.0000
18:21532676:A:C	acceptor_gain	1.0000
18:21536036:ACTT:A	donor_loss	1.0000
18:21536037:CTTA:C	donor_loss	1.0000
18:21536038:TTA:T	donor_loss	1.0000
18:21536039:TACCC:T	donor_loss	1.0000
18:21536040:A:AC	donor_gain	1.0000
18:21536040:A:AG	donor_loss	1.0000
18:21536040:AC:A	donor_gain	1.0000
18:21536041:C:CC	donor_gain	1.0000
18:21536041:CC:C	donor_gain	1.0000
18:21536041:CCCA:C	donor_gain	1.0000
18:21538651:T:A	donor_gain	1.0000
18:21540635:A:AC	donor_gain	1.0000
18:21540636:C:CC	donor_gain	1.0000
18:21540639:A:AC	donor_gain	1.0000
18:21540640:A:C	donor_gain	1.0000
18:21560852:CACTT:C	donor_loss	1.0000

AlphaMissense

5594 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
18:21530382:A:C	F828L	1.000
18:21530382:A:T	F828L	1.000
18:21530383:A:G	F828S	1.000
18:21530384:A:G	F828L	1.000
18:21530410:G:T	A819E	1.000
18:21530413:A:G	F818S	1.000
18:21530422:C:A	G815V	1.000
18:21530422:C:T	G815E	1.000
18:21530423:C:G	G815R	1.000
18:21530423:C:T	G815R	1.000
18:21530434:G:T	P811H	1.000
18:21530443:A:G	F808S	1.000
18:21530446:G:T	A807D	1.000
18:21532476:A:G	L791P	1.000
18:21532497:G:T	A784D	1.000
18:21532513:G:T	R779S	1.000
18:21532529:C:A	W773C	1.000
18:21532529:C:G	W773C	1.000
18:21532531:A:G	W773R	1.000
18:21532531:A:T	W773R	1.000
18:21532533:A:T	I772K	1.000
18:21532536:C:G	R771P	1.000
18:21532545:C:T	G768E	1.000
18:21532546:C:A	G768W	1.000
18:21532546:C:G	G768R	1.000
18:21532546:C:T	G768R	1.000
18:21532547:G:C	C767W	1.000
18:21532549:A:G	C767R	1.000
18:21532582:A:G	W756R	1.000
18:21532582:A:T	W756R	1.000

dbSNP variants (sampled 300 via entrez): RS1000034781 (18:21575110 G>C,T), RS1000108002 (18:21575421 G>A), RS1000148418 (18:21541355 C>G,T), RS1000197900 (18:21561331 T>C), RS1000226234 (18:21529631 T>C), RS1000262727 (18:21567705 C>T), RS1000270737 (18:21575370 C>G), RS1000315671 (18:21581554 T>C), RS1000466727 (18:21569331 C>T), RS1000515575 (18:21593462 C>A,T), RS1000550390 (18:21545003 G>T), RS1000560980 (18:21600320 C>G), RS1000610653 (18:21544704 A>C,T), RS1000620482 (18:21595928 C>T), RS1000633996 (18:21529283 C>T)

Disease associations

OMIM: gene MIM:609674 | disease phenotypes: MIM:601076

GenCC curated gene-disease

Mondo (1): Mayer-Rokitansky-Küster-Hauser syndrome type 2 (MONDO:0010989)

Orphanet (2): Mayer-Rokitansky-Küster-Hauser syndrome type 2 (Orphanet:2578), Mayer-Rokitansky-Küster-Hauser syndrome (Orphanet:3109)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST010703_44	Brain morphology (MOSTest)	1.000000e-08

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004346	neuroimaging measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
trichostatin A	affects cotreatment, decreases expression	3
methylmercuric chloride	increases expression	2
sodium arsenite	decreases expression, increases abundance	2
perfluorooctane sulfonic acid	decreases expression	2
Aflatoxin B1	decreases methylation, increases methylation	2
aristolochic acid I	decreases expression	1
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
GSK-J4	increases expression	1
FR900359	affects phosphorylation	1
dicrotophos	decreases expression	1
geldanamycin	increases expression	1
triphenyl phosphate	affects expression	1
arsenite	affects binding, decreases reaction	1
zinc chromate	increases abundance, increases expression	1
manganese chloride	increases abundance, increases expression	1
chromium hexavalent ion	increases expression, increases abundance	1
2-palmitoylglycerol	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Vorinostat	decreases expression	1
Leflunomide	increases expression	1
Arsenic	decreases expression, increases abundance	1
Benzo(a)pyrene	increases methylation	1
Cadmium	increases abundance, increases expression	1
Caffeine	decreases phosphorylation	1
Cisplatin	decreases expression	1
Clorgyline	increases expression	1
Dichlorodiphenyl Dichloroethylene	decreases expression	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E1WF	HAP1 ESCO1 (-) 1	Cancer cell line	Male
CVCL_E1WG	HAP1 ESCO1 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.